Benefits
- Benefit
-
Adenoma detection rose from 50.7% to 54.9%
Awaiting review
- Outcome identifiers
-
Unresolved
Not reviewedUnresolved
- Category
-
Improved Task Accuracy
Awaiting review
- Status
-
Reported benefit
Awaiting review
- Beneficiary groups
-
People. Organizations.
Awaiting review
- Beneficiaries
-
Unresolved
Not reviewedUnresolved
- Reach
-
Unresolved
Not reviewedUnresolved
- Distribution and access
-
Unresolved
Not reviewedUnresolved
- Duration
-
Unresolved
Not reviewedUnresolved
- Expected?
-
Yes
Awaiting review
- Costs and harms
-
Unresolved
Not reviewedUnresolved
AI system
- System
-
GI Genius Intelligent Endoscopy Module
Awaiting review
- Model
-
This is an explicit unresolved assignment: the sources on record do not settle this question.
Not reviewedUnresolved
- Release
-
Unresolved
Not reviewedUnresolved
- Provider
-
Unresolved
Not reviewedUnresolved
- Role
-
Unresolved
Not reviewedUnresolved
- Configuration
-
Unresolved
Not reviewedUnresolved
- Inputs and outputs
-
Unresolved
Not reviewedUnresolved
- Autonomy
-
Unresolved
Not reviewedUnresolved
- Workflow
-
The VA installed the devices at facilities chosen at random. Endoscopists used the device during routine colonoscopy. Baseline adenoma detection at the facilities was already about 51%.
Awaiting review
- Human oversight
-
Unresolved
Not reviewedUnresolved
- Relation to AI
-
Facilities were assigned at random to receive the device, and the authors compare the change in adenoma detection at equipped facilities with the change at control facilities over the same period.
Awaiting review
- AI contribution
-
Facilities were assigned at random to receive the device, and the authors compare the change in adenoma detection at equipped facilities with the change at control facilities over the same period.
Awaiting review
Measurement
- Studies
-
Randomized. [2]
Fully reviewed: supporting details for Studies
Review date: 29 October 2026.
Sources: [2]
- Study design
-
Randomized. [2]
Fully reviewed: supporting details for Study design
Review date: 29 October 2026.
Sources: [2]
- Measurement
-
Adenoma detection from VA colonoscopy and pathology records before and after deployment; mixed effects logistic regression. [2]
Fully reviewed: supporting details for Measurement
Review date: 29 October 2026.
Sources: [2]
- Setting and sample
-
269 endoscopists at 42 equipped facilities and 547 at 97 control facilities; 334,200 colonoscopies. [2]
Fully reviewed: supporting details for Setting and sample
Review date: 29 October 2026.
Sources: [2]
- Measures
-
Adenoma detection rate. [2]
Fully reviewed: supporting details for Measures
Review date: 29 October 2026.
Sources: [2]
- Comparison
-
Control facilities with a random deployment date. [2]
Fully reviewed: supporting details for Comparison
Review date: 29 October 2026.
Sources: [2]
- Results
-
+4.2 percentage points (50.7% to 54.9%) at equipped facilities against -0.7 points at control facilities; odds ratio 1.22. [2]
Fully reviewed: supporting details for Results
Review date: 29 October 2026.
Sources: [2]
- Additional value from AI
-
Odds ratio 1.22 (95% CI 1.15 to 1.28). [2]
Fully reviewed: supporting details for Additional value from AI
Review date: 29 October 2026.
Sources: [2]
- Limitations
-
Facility-level randomization; no data on cancer outcomes; deskilling not assessed. [2]
Fully reviewed: supporting details for Limitations
Review date: 29 October 2026.
Sources: [2]
Money
- Kind of value
-
The kind of monetary value is unclear.
Not reviewedUnresolved
- Amount
-
The monetary value is not established.
Not reviewedUnresolved
- Currency and prices
-
The currency and price basis are unclear.
Not reviewedUnresolved
- Period and unit
-
The period and unit of the monetary estimate are unclear.
Not reviewedUnresolved
- Realization
-
Whether the monetary value was realized is unclear.
Not reviewedUnresolved
- Recipients and payers
-
The recipients and payers are unclear.
Not reviewedUnresolved
- Gross or net
-
Whether the monetary figure includes costs is unclear.
Not reviewedUnresolved
- Included costs
-
The costs included in the estimate are unclear.
Not reviewedUnresolved
- Comparison
-
The financial comparison is not established.
Not reviewedUnresolved
- Method
-
The method used to calculate monetary value is unclear.
Not reviewedUnresolved
- Return and payback
-
The return on investment or payback period is not established.
Not reviewedUnresolved
People and places
- Participants
-
Developer: Medtronic. Operator: Veterans Health Administration, National Gastroenterology and Hepatology Program.
Awaiting review
- Jurisdictions
-
Benefit: 42 VA medical facilities,
United States. Developer: 
Ireland. Operator: United States.Awaiting review
- Ownership and control
-
Unresolved
Not reviewedUnresolved
- Dependencies
-
Unresolved
Not reviewedUnresolved
- Cross-border connections
-
Unresolved
Not reviewedUnresolved
- Geopolitical implications
-
The geopolitical implications are unclear.
Not reviewedUnresolved
Follow-up
- Conditions for replication
-
Endoscopists must keep using the device once it is installed. The gain must not fade as endoscopists grow used to the alerts.
Awaiting review
- Replication attempts
-
2 follow-up entries. Benefit recurred: 1. Benefit did not recur: 1.
Awaiting review
- Later findings
-
Unresolved
Not reviewedUnresolved
- Availability
-
Unresolved
Not reviewedUnresolved
- Institutional decision
-
A relevant institutional decision has not been established.
Not reviewedUnresolved
- Grounds
-
The grounds for an institutional decision are unclear.
Not reviewedUnresolved
- Action and result
-
The result of an institutional decision is not established.
Not reviewedUnresolved
- Success criterion
-
The criterion for a successful institutional decision is unclear.
Not reviewedUnresolved
Evidence
- Source numbers
-
AIBD-0645-source-0001–0002
Awaiting review
- Citations
-
Numbered references below.
Awaiting review
- Language
-
Unresolved
Not reviewedUnresolved
- Source relationships
-
Independent, Operator
Awaiting review
- Original evidence
-
Unresolved
Not reviewedUnresolved
- Access and versions
-
Unresolved
Not reviewedUnresolved
- Supported findings
-
Unresolved
Not reviewedUnresolved
- Evidence links
-
Unresolved
Not reviewedUnresolved
- Evidence strength
-
Independently studied. Sources: one independent peer-reviewed study and the deployer's peer-reviewed study. The cited evidence includes no finding by a regulator or court. [1] [2]
- Missing evidence
-
Unresolved
Not reviewedUnresolved
Grades
- Assessed benefits
-
People. Organizations.
Awaiting review
- Depth
-
People: 3. Organizations: 2.
Awaiting review
- Reasons
-
People: More veterans had precancerous adenomas found and removed: detection rose from 50.7% to 54.9% of colonoscopies at equipped facilities. Organizations: The VA raised a core colonoscopy quality measure by 4.2 percentage points without a change in withdrawal time.
Awaiting review
- Observed or intended
-
Unresolved
Not reviewedUnresolved
- Rubric
-
Unresolved
Not reviewedUnresolved
- Assessor and date
-
Unresolved
Not reviewedUnresolved
- Alternative assessments
-
Unresolved
Not reviewedUnresolved
- Fill
-
Independently studied
Awaiting review
Entry details
- Kind
-
The case describes an evaluation or a study. A pragmatic cluster-randomized quality improvement study. [1]
Fully reviewed: supporting details for Kind
Review date: 29 October 2026.
Sources: [1]
- Related entries
-
No incident in the AI Incident Database snapshot of 26 October 2026 concerns the same kind of system harming the same kind of stakeholder.
Partly reviewedUnresolved: supporting details for Related entries
Compared with the incidents in the AI Incident Database snapshot of 26 October 2026.
- Field
-
Healthcare.
Awaiting review
- Purpose
-
GI Genius was built to flag possible polyps on the colonoscopy video in real time. The higher adenoma detection was that purpose.
Awaiting review
- Dates
-
Observed: October 2022. Updated: 29 October 2026.
Awaiting review
- Stage
-
The system was in routine use. Devices were installed for routine colonoscopy at 42 VA facilities. [1]
Fully reviewed: supporting details for Stage
Review date: 29 October 2026.
Sources: [1]
- Version
-
SHA-256: 4e54d2f0b4fc…
Awaiting review: supporting details for Version
SHA-256 of the public case, its assessments, and its displayed answers and notes, excluding its own identifier and the derived coverage summary.
References
- Other identifiers
-
Unresolved
Not reviewedUnresolved
- Category mappings
-
Unresolved
Not reviewedUnresolved
- Citable summary
-
Unresolved
Not reviewedUnresolved
- Revisions
-
1 revision. Latest: 29 October 2026.
Awaiting review
Sources
-
Peer-reviewed study Independent author
Routine-practice studies have sometimes reported smaller benefits than conventional randomized trials, although a large pragmatic cluster-randomized study found that an ADR benefit could be retained at scale
-
Peer-reviewed study Deployer
Dominitz JA, Gawron AJ, McKee GB, Hoggatt KJ, Kaltenbach T. Impact of Availability of Computer-Aided Detection Devices on Adenoma Detection During Colonoscopy: A Cluster Randomized Study. Gastroenterology. 2026;171(5):870-884. doi:10.1053/j.gastro.2026.05.018
Comparing post- with predeployment colonoscopies, the absolute increase in ADR was 4.2 percentage points (95% CI, 3.48 to 4.74 percentage points), from 50.7% to 54.9%, at CADe sites and ADR decreased by 0.7 percentage points (95% CI, -1.16 to -0.28 percentage points), from 51.8% to 51.1%, at control sites.